Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells

Cancer Research

Volumn 56, Issue 21, 1996, Pages 4856-4861

  Bible, Keith C ^a   Kaufmann, Scott H ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; ANTINEOPLASTIC AGENT; CYCLOHEXIMIDE; FLAVONE DERIVATIVE; FLAVOPIRIDOL; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL DEATH; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RNA SYNTHESIS;

ANTINEOPLASTIC AGENTS; APHIDICOLIN; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; CYCLOHEXIMIDE; FLAVONOIDS; HUMANS; LUNG NEOPLASMS; PIPERIDINES; TUMOR CELLS, CULTURED;

EID: 0029904810     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Maik, R. G, Kattice, S. L, Bhat, S V., Alreja, B., de Souza, N J., and Rupp, R. H. An anti-inflammatory cum immunomodulatory piperidinylbenzopyranone from Dysoxylum binectariferum isolation, structure and total synthesis. Tetrahedron, 44, 2081-2086, 1988.
2. Senderowicz, A M, Headlee, D., Stinson, S., Lush, R. M, Tompkins, A, Brawley, O, Bergan, R., Figg, W. D., Smith, A, and Sausville, E A. Phase I trial of a novel cyclin-dependent kinase inhibitor flavopiridol in patients with refractory neoplasms. National Cancer Institute-European Organization for Research on Treatment of Cancer Symposium Proceedings, p 77, 1996.
3. Kaur, G, Stetler-Stevenson, M, Sebers, S., Worland, P., Sedlacek, H., Myers, C, Czech, J., Naik, R, and Sausville, E Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst., 84 1736-1740, 1992
4. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res, 56: 2973-2978, 1996
5. Carlson, B. A, Pearlstem, R. A, Naik, R G, Sedlacek, H-H, Sausville, E. A., and Worland, P J. Inhibition of CDK2, CDK4, and CDK7 by flavopiridol and structural analogues Proc Am. Assoc. Cancer Res, 37: 424, 1996.
6. Losiewicz, M. D., Carlson, B. A., Kaur, G, Sausville, E A, and Worland, P. J Potent inhibition of CDC2 kinase activity by the flavonoid L86-S275. Biochem Biophys Res. Commun., 201, 589-595, 1994
7. Filgueira de Azevedo, W, Mueller-Dieckmann, H-J., Schulze-Gahmen, U, Worland, P. J., Sausville, E., and Kim, S-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase Proc. Natl Acad. Sci. USA, 93: 2735-2740, 1996
8. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells Correlation with decreased H1 kinase activity. Biochem. Pharmacol., 46: 1831-1840, 1993.
9. Drees, M, Berger, D. P, Dengler, W A, Labonte, H., Mayo, J., Malspeis, L, Sausville, E, Grever, M., and Fiebig, H. H L86-8275, a new flavone with selectivity in prostate cancers in vitro and in vivo. Proc. Am. Assoc. Cancer Res, 35, A2793, 1994.
10. Hendricks, C B., Rowinsky, E. K., Grochow, L. B, Donehower, R. C., and Kaufmann, S. H. Effect of p-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res, 52 2268-2278, 1992
11. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 51, 1129-1136, 1991.
12. Buckwalter, C A, Lin, A H., Tanizawa, A., Pommier, Y G., Cheng, Y-C., and Kaufmann, S. H. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res., 56: 1647-1681, 1996
13. Mesner, P., Budihardjo, I., and Kaufmann, S. H. Chemotherapy-induced apoptosis. In. S. H. Kaufmann (ed.), Apoptosis: Pharmacology and Therapeutics. San Diego: Academic Press, in press, 1997.
14. Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N., and Poirier, G. G. Specific proteolytic fragmentation of poly(ADP-ribose) polymerase. An early marker of chemotherapy-induced apoptosis. Cancer Res., 53: 3976-3985, 1993.
15. Boege, F, Straub, T., Kehr, A., Boesenberg, C., Chnstiansen, K, Andersen, A., Jakob, F, and Kohrle, J. Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I. J Biol. Chem., 271, 2262-2270, 1996.
16. Parker, B W, Senderowicz, A. M . Nieves-Neira, W, Pommier, Y., and Sausville, E. A. DNA fragmentation and apoptosis of lymphoma and prostate cancer cell lines after flavopiridol treatment Proc. Am. Assoc Cancer Res., 37: 398, 1996
17. Schwartz, G K., Farsi, K., Danso, D., Dhupar, S. K., Kelsen, D, and Spriggs, D The protein kinase C (PKC) inhibitors UCN-01 and flavopiridol (FLAVO) significantly enhance the cytotoxic effect of chemotherapy by promoting apoptosis in gastric and breast cancer cells. Proc Am Soc. Clin Oncol., 15: 207, 1996
18. Tannock, I. F. Principles of cell proliferation: cell kinetics. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 3-13. Philadelphia: J B Lippincott, 1989.
19. Drewinko, B., Patchen, M., Yang, L-Y., and Barlogie, B. Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells Cancer Res, 41: 2328-2333, 1981